Aytu Biopharma Reports Fiscal 2025 Results: Net Revenue Rises to $66.4 Million, Net Loss at $13.6 Million, Adjusted EBITDA Reaches $9.2 Million

Reuters09-24
Aytu Biopharma Reports Fiscal 2025 Results: Net Revenue Rises to $66.4 Million, Net Loss at $13.6 Million, Adjusted EBITDA Reaches $9.2 Million

Aytu Biopharma Inc. released its fiscal 2025 full year and fourth quarter financial results, reporting a full year net revenue of $66.4 million and a net loss of $13.6 million. Adjusted EBITDA for the year was $9.2 million, with a cash balance of $31 million as of June 30, 2025. For the fourth quarter of fiscal 2025, net revenue saw a 4% increase to $15.1 million compared to $14.6 million in the fourth quarter of fiscal 2024. The ADHD portfolio generated net revenue of $13.1 million, a slight decrease from $13.8 million in the same period of the previous year. The Pediatric Portfolio, however, showed an increase, with net revenue rising to $2.0 million from $0.8 million in the prior year's fourth quarter. The net loss for the fourth quarter was $19.8 million, significantly higher than the $4.6 million loss recorded in the fourth quarter of fiscal 2024, impacted by $18.1 million in combined impairment expense and derivative warrant liabilities loss. Adjusted EBITDA remained stable at $2.0 million for both the fourth quarter of fiscal 2025 and 2024. In a significant business update, Aytu Biopharma outlined plans for the commercial launch of EXXUA, an extended-release tablet for major depressive disorder, expected to occur in the fourth calendar quarter of 2025. The company anticipates that EXXUA will be a key growth catalyst as it enters the over $22 billion United States prescription market for major depressive disorder. Management has expressed optimism about transforming Aytu into a leader in addressing complex CNS diseases through this new product launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076810) on September 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment